Microbiome

An average person contains 30 trillion human cells, but even more microbes – about 39 trillion. In addition, there are possibly ten times that number of viral particles in the human virome. Understanding an individual’s microbiome is becoming increasingly important for diagnosing a broad range of diseases.

Patents that relate to the microbiome often need to be drafted differently from patents covering small molecule drugs or conventional diagnostics. For instance, some inventions lie in a way of affecting or detecting a heterogenous population of microbial cells. The cells could be defined in various ways, such as by their function or by their degree of genetic relatedness to a reference organism. Other inventions lie in a way of assessing the impact of the heterogenous population of microbes on drug metabolism, which might require functional definitions and/or specific assays to be written into the claims.

Applicants for microbiome-based patents need to be aware of legal obstacles in certain jurisdictions that would make certain claims very difficult to obtain. At Mewburn Ellis LLP, our world class training and broad experience makes us an excellent choice to be your creative, trusted advisors in this rapidly developing space.

Open pages of EPO Opposition Trends in the Life Sciences Sector

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

UPC Weekly - High bar to challenge the jurisdiction of the UPC

UPC Weekly - High bar to challenge the jurisdiction of the UPC

2024 Week 19 This week saw the UPC issue two decisions about its own jurisdiction. Where a defendant wants to challenge the jurisdiction of the UPC to hear a dispute, they must file a preliminary ...

Bacteria bites back: Putting carbon on the menu

Bacteria bites back: Putting carbon on the menu

When faced with solving the climate crisis, no idea is too ambitious for Synthetic Biology (SynBio) scientists. While SynBio has already underpinned a range of innovative climate-saving technologies ...

UPC Weekly - Preliminary injunctions at the UPC – get your defence ready

UPC Weekly - Preliminary injunctions at the UPC – get your defence ready

2024 Week 18 This week we look at a recent UPC first instance decision for a preliminary injunction. The message being sent by the UPC to patent proprietors is clear. The UPC is ready and willing to ...

Our clients are at the heart of our Trade Mark business

Our clients are at the heart of our Trade Mark business

We are delighted to release our latest brochure 'Our clients are at the heart of our Trade Mark business'.

UPC Weekly - Battling the Biosimilars: opt-outs, preliminary injunctions & protective letters

UPC Weekly - Battling the Biosimilars: opt-outs, preliminary injunctions & protective letters

2024 Week 17 This week we delve into the details of the first two UPC disputes involving biosimilars. Alexion Pharmaceuticals have launched UPC proceedings against Amgen and Samsung, while Novartis ...

Cleantech Commercialisation Report: Highlights and Trends

Cleantech Commercialisation Report: Highlights and Trends

Today (26 April 2024) the European Patent Office (EPO) and the European Investment Bank (EIB) published an in-depth (and very lengthy) report on financing and commercialisation of cleantech. [For ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.